Slide 1: CELL BIOTECH 2025 2Q Earnings Release
CELL BIOTECH Probiotics & Microbiome company 2025 2Q Earnings Release 2025. 08. As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual result
Slide 2: Revenue down 5.2% to KRW 11.9 billion, operating profit down 49%
CELL BIOTECH Revenue down 5.2% to KRW 11.9 billion, operating profit down 49% to KRW 1.3 billion Domestic revenue up 3.5%, overseas revenue down 12.6% Duolac brand sales up 14.8% to KRW 6.9 billion, OEM/ODM sales down 33.3% to KRW 3.2 billion, Raw material sales up 2.5% to KRW 1.8 billion (unit : KR
Slide 3: Quarterly revenue and full year revenue
CELL BIOTECH 2q revenue KRW 11.9 billion, yoy -5.2%, qoq +6.1% Quarterly revenue Full year revenue (unit : KRW mil) (unit : KRW mil) 53,787 50,526 49,913 14,841 13,660 13,038 12,440 12,558 12,160 12,155 11,910 11,229 46,873 2021 2022 2023 2024 3
Slide 4: Quarterly profit and full year profit
CELL BIOTECH 2q operating profit KRW 1.3 billion, yoy -48.9% Net Profit KRW +0.2 bil. Quarterly profit Full year profit (unit : KRW mil) 15,127 OP NP 6,860 10,314 4,040 9,682 3,260 2,961 2,707 2384 2,070 7,258 2080 6,796 1,812 2510 6,273 6,304 1362 1280 1070 960 1130 210 '23.2Q '23.3Q '23.4Q '24.1Q
Slide 5: 2Q revenue by Duolac brand, OEM/ODM and raw material
CELL BIOTECH 2q revenue of Duolac brand +14.8% to 6.9 KRW bil., OEM/ODM -33.3% to 3.2 KRW bil., and raw material +2.5% to 1.8 KRW bil. 20,000 (unit : KRW mil) 15,000 10,000 5,000 - 22.2Q 22.3Q 22.4Q 23.1Q 23.2Q 23.3Q 23.4Q 24.1Q 24.2Q 24.3Q 24.4Q 25.1Q 25.2Q Duolac-domestic Duolac-overseas OEM/ODM r
Slide 6: Microbiome R&D
CELL BIOTECH Microbiome R&D No. 1 in global export for 12 consecutive years 1) Microbiome First-in-Class anticancer pipeline ‘PP-P8’ 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 clinical phase 1 IND submitted (Mar 5, 2021) in the world for 12 consecutive years 2) Acquisition European patent of
Slide 7: FDA GRAS World's Most Listed
CELL BIOTECH FDA GRAS World’s Most Listed 1) Cellbiotech "11 types of lactic acid bacteria secured 2) Cellbiotech, Probiotics Leading... Global Leap FDA GRAS certification... The World's Largest Holdings" https://www.hankyung.com/article/202402222016i https://www.dailypharm.com/Users/News/NewsVie w.
Slide 8: Income statement and statement of financial position
CELL BIOTECH Income statement Statement of financial position (unit : KRW 100 mil., %) (unit : KRW 100 mil., %) 2024 2q 2025 2q 2024 .12 2025 .2Q Amount Ratio Amount Ratio Assets 1,304 1,296 Revenue 125.6 100 119.1 100 Current Assets 972 973 Gross profit 92.0 73.2 88.9 74.6 Non current Assets 332 32